Literature DB >> 27004002

Application of gemstone spectral imaging for efficacy evaluation in hepatocellular carcinoma after transarterial chemoembolization.

Qi-Yu Liu1, Chuan-Dong He1, Ying Zhou1, Dan Huang1, Hua Lin1, Zhong Wang1, Dong Wang1, Jin-Qiu Wang1, Li-Ping Liao1.   

Abstract

AIM: To assess the value of gemstone spectral imaging (GSI) in efficacy evaluation in hepatocellular cancer (HCC) after transcatheter arterial chemoembolization (TACE) treatment.
METHODS: Thirty patients with HCC underwent GSI, including nonenhanced, arterial, portalvenous and delayed phase scans, after TACE treatment. Arterial phase images were acquired with GSI for reconstruction of virtual nonenhanced images and color overlay images. Digital subtraction angiography (DSA) was performed in all these patients. Two blinded and independent readers evaluated the data in two reading sessions; standard nonenhanced, arterial, portalvenous, and delayed phase images were read in session A, and the optimal monochromatic images, iodine/water based images and spectrum features were read in session B. Sensitivity and specificity were calculated with the DSA data as the reference standard. The sensitivity and specificity were compared using the χ (2) test.
RESULTS: DSA revealed 154 lesions in 30 patients, and 100 of them had blood supply. Overall sensitivity and specificity were 72% (72/100) and 77.8% (42/54) for session A, and 97% (97/100) and 94.4% (51/54) for session B, respectively. The sensitivity and specificity of the two reading sessions were significantly different (χ (2) = 23.04, χ (2) = 7.11, P < 0.05).
CONCLUSION: Compared with conventional CT, GSI could significantly improve the detection of small and multiple lesions without increasing the radiation dose. Based on spectrum features, GSI could assess tumor homogeneity and more accurately identify residual tumors and recurrent or metastatic lesions during efficacy evaluation and follow-up in HCC after TACE treatment.

Entities:  

Keywords:  Digital subtraction angiography; Efficacy evaluation; Gemstone spectral imaging; Hepatocellular carcinoma; Transcatheter arterial chemoembolization

Mesh:

Substances:

Year:  2016        PMID: 27004002      PMCID: PMC4790000          DOI: 10.3748/wjg.v22.i11.3242

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI.

Authors:  K Kubota; N Hisa; T Nishikawa; Y Fujiwara; Y Murata; S Itoh; D Yoshida; S Yoshida
Journal:  Abdom Imaging       Date:  2001 Mar-Apr

2.  Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography.

Authors:  Yasunori Minami; Masatoshi Kudo; Toshihiko Kawasaki; Masayuki Kitano; Hobyung Chung; Kiyoshi Maekawa; Hitoshi Shiozaki
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

3.  Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images.

Authors:  Hyo-Cheol Kim; Ah Young Kim; Joon Koo Han; Jin Wook Chung; Jae Young Lee; Jae Hyung Park; Byung Ihn Choi
Journal:  Radiology       Date:  2002-12       Impact factor: 11.105

4.  Detection of hypervascular hepatocellular carcinoma: Comparison of multi-detector CT with digital subtraction angiography and Lipiodol CT.

Authors:  Xiao-Hua Zheng; Yong-Song Guan; Xiang-Ping Zhou; Juan Huang; Long Sun; Xiao Li; Yuan Liu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

5.  Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.

Authors:  Kenichi Takayasu; Shigeki Arii; Iwao Ikai; Masao Omata; Kiwamu Okita; Takafumi Ichida; Yutaka Matsuyama; Yasuni Nakanuma; Masamichi Kojiro; Masatoshi Makuuchi; Yoshio Yamaoka
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

6.  Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization: comparison of contrast-enhanced sonography and 3-phase computed tomography.

Authors:  Hyun Jin Kim; Tae Kyoung Kim; Pyo Nyun Kim; Ah Young Kim; Eun Young Ko; Kyoung Won Kim; Kyu-Bo Sung; Hyun Kwon Ha; Hyun Cheol Kim; Moon-Gyu Lee
Journal:  J Ultrasound Med       Date:  2006-04       Impact factor: 2.153

7.  Multi-detector row helical CT in preoperative assessment of small (< or = 1.5 cm) liver metastases: is thinner collimation better?

Authors:  Masoom A Haider; Marianne M Amitai; Daniel C Rappaport; Martin E O'Malley; Anthony E Hanbidge; Mark Redston; Gina A Lockwood; Steven Gallinger
Journal:  Radiology       Date:  2002-10       Impact factor: 11.105

8.  Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images?

Authors:  Anno Graser; Thorsten R C Johnson; Elizabeth M Hecht; Christoph R Becker; Christianne Leidecker; Michael Staehler; Christian G Stief; Henriette Hildebrandt; Myrna C B Godoy; Myra E Finn; Flora Stepansky; Maximilian F Reiser; Michael Macari
Journal:  Radiology       Date:  2009-06-01       Impact factor: 11.105

Review 9.  Novel advancements in the management of hepatocellular carcinoma in 2008.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

Review 10.  Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period.

Authors:  Do Seon Song; Si Hyun Bae
Journal:  Clin Mol Hepatol       Date:  2012-09-25
View more
  1 in total

1.  Iodine concentration: a new, important characteristic of the spot sign that predicts haematoma expansion.

Authors:  Fan Fu; Shengjun Sun; Liping Liu; Jianying Li; Yaping Su; Yingying Li
Journal:  Eur Radiol       Date:  2018-04-19       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.